John Moller, Novotech CEO

Novotech's lat­est ac­qui­si­tions grow its US pres­ence and plant a Eu­ro­pean foothold

Over the past few years, the CRO Novotech has ce­ment­ed its po­si­tion in the Asia-Pa­cif­ic re­gion, but its lat­est move will see it plant­i­ng its flag on two dif­fer­ent con­ti­nents.

On Mon­day, Novotech an­nounced it has ac­quired two CROs: the Col­orado-based CBR In­ter­na­tion­al and the Poland-based east­HORN.

CBR is a con­sul­tan­cy com­pa­ny fo­cused on guid­ing phar­ma com­pa­nies through FDA re­quire­ments and of­fers ser­vices that in­clude reg­u­la­to­ry strat­e­gy, FDA rep­re­sen­ta­tion and sci­en­tif­ic af­fairs to sup­port cGMP re­quire­ments, among oth­ers. The ac­qui­si­tion will now al­low Novotech to add US and glob­al reg­u­la­to­ry, qual­i­ty and de­vel­op­ment ser­vices to its ar­se­nal. This in­cludes as­sist­ing with sub­mis­sions such as IND, BLA, fast track and or­phan drug ap­pli­ca­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.